4-[(4-methoxyphenyl)methyl]-1(2H)-phthalazinone | 57835-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-[(4-methoxyphenyl)methyl]-1(2H)-phthalazinone
• 英文别名: 4-(4-methoxybenzyl)phthalazin-1(2H)-one；4-(4-methoxy-benzyl)-2H-phthalazin-1-one；4-(4-Methoxy-benzyl)-2H-phthalazin-1-on；4-{[4-(methyloxy)phenyl]methyl}-1(2H)-phthalazinone；4-(4-Methoxy-benzyl)-3H-phtalaz-1-on；4-[(4-methoxyphenyl)methyl]-2H-phthalazin-1-one
• CAS: 57835-95-7
• 化学式: C₁₆H₁₄N₂O₂
• 分子量: 266.299
• InChiKey: CUGWYAVRVHQTNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(4-methoxyphenyl)methyl]-1(2H)-phthalazinone 在 偶氮二甲酸二叔丁酯 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.75h， 生成 4-[(4-methoxyphenyl)methyl]-2-[(2R)-2-pyrrolidinylmethyl]-1(2H)-phthalazinone
  参考文献：
  名称：

  The Discovery of Phthalazinone-Based Human H₁ and H₃ Single-Ligand Antagonists Suitable for Intranasal Administration for the Treatment of Allergic Rhinitis

  摘要：

  A series of potent phthalazinone-based human H-1 and H-3 bivalent histamine receptor antagonists, suitable for intranasal administration for the potential treatment of allergic rhinitis, were identified. Blockade of H-3 receptors is thought to improve efficacy on nasal congestion, a symptom of allergic rhinitis that is currently not treated by current antihistamines. Two analogues (56a and 56b) had slightly lower H-1, potency (pA(2) 9.1 and 8.9, respectively, vs 9.7 for the clinical gold-standard azelastine, and H-3 potency (pK(i) 9.6 and 9.5, respectively, vs 6.8 for azelastine). Compound 56a had longer duration of action than azelastine, low brain penetration, and low oral bioavailability, which coupled with the predicted low clinical dose, should limit the potential of engaging CNS-related side-effects associated with H-1 or H-3 antagonism.

  DOI：

  10.1021/jm1013874
• 作为产物：
  描述：

  对甲氧基苯乙酸 在 sodium acetate 、 sodium hydroxide 、 硫酸肼 作用下， 以 乙醇 为溶剂， 反应 20.0h， 生成 4-[(4-methoxyphenyl)methyl]-1(2H)-phthalazinone
  参考文献：
  名称：

  通过扩展其与活性位点之间的疏水性相互作用来提高VEGFR-2抑制剂的结合亲和力：1-取代的4-（4-甲氧基苄基）酞嗪衍生物的设计，合成和生物学评估

  摘要：

  最初合成了一系列 苯并酞菁衍生物4a – j，并测试了其对VEGFR-2的抑制活性，并显示出有希望的活性（IC 50 = 0.636–5.76μM）。分子对接研究指南用于改善4a – j系列的结合亲和力朝向VEGFR-2活性位点。通过增加与衬有Ile888，Leu889，Ile892，Val898，Val899，Leu1019和Ile1044的疏水性侧链的VEGFR-2活性位点的疏水性后口袋的疏水性相互作用，实现了这一改进。疏水相互作用的增强是通过将带有取代苯基部分的苯胺基酞嗪支架通过一个uriedo接头延伸而实现的，这应为该延伸提供足够的灵活性，以使其自身能够深深地容纳在疏水性后袋中。按计划，设计的尿酸-苯胺基酞嗪7a – i的结合亲和力比其苯胺基 酞嗪母体好（IC 50 = 0.083–0.473μM）。特别是化合物7g – i的IC 50分别为0.086、0.083和0.086μM，优于参考药物索拉非尼（IC

  DOI：

  10.1016/j.ejmech.2016.02.029

文献信息

• Tuning Selectivity of Anionic Cyclizations: Competition between 5-Exo and 6-Endo-Dig Closures of Hydrazides of <i>o-</i>Acetylenyl Benzoic Acids and Based-Catalyzed Fragmentation/Recyclization of the Initial 5-Exo-Dig Products
  作者：Sergey F. Vasilevsky、Tat’yana F. Mikhailovskaya、Victor I. Mamatyuk、Georgy E. Salnikov、Georgy A. Bogdanchikov、Mariappan Manoharan、Igor V. Alabugin

  DOI：10.1021/jo901551g

  日期：2009.11.6

  nucleophile is controlled by the nature of alkyne substituents under the kinetic control conditions. In the presence of KOH, the initially formed 5-exo products undergo a new rearrangement that involves a ring-opening followed by recyclization to the formal 6-exo-products and rendered irreversible by a prototropic isomerization. DFT computations provide insight into the nature of factors controlling relative

  根据反应条件和三键上取代基的性质，邻位酰肼的阴离子环化乙炔基苯甲酸可选择性地沿着三种替代途径被引导，每种途径均能有效地进入不同类别的氮杂环。“内部”氮亲核试剂的5-exo和6-endo环化之间的竞争由动力学控制条件下炔烃取代基的性质控制。在KOH的存在下，最初形成的5-exo产物经历了新的重排，该新的重排涉及开环，然后环化成正式的6-exo产物，并且由于质子异构化而变得不可逆。DFT计算可洞悉控制5-exo，6-endo和6-exo环化路径的相对速率的因素的性质，从而确定直接进行6-exo封闭的可行性以及该过程中阴离子前体的相对稳定性，首次获得了几类阴离子氮环化的基准数据，并剖析了控制环阴离子中间体相对稳定性并影响反应立体选择性的立体电子效应。我们表明，在这种情况下，通过将稳定的氮阴离子转变为本质上不稳定的碳负离子，可以抵消由于将弱的π键转变为更强的σ键（炔烃环化的通常驱动力）而获得的稳定
• Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds
  作者：Hany S. Ibrahim、Wagdy M. Eldehna、Hatem A. Abdel-Aziz、Mahmoud M. Elaasser、Marwa M. Abdel-Aziz

  DOI：10.1016/j.ejmech.2014.08.016

  日期：2014.10

  phthalazine moiety. Similarly, our strategy in this research depends on the interconnection between some sulfa drugs and certain phthalazin-1(2H)-one scaffolds in an attempt to enhance their antibacterial activity. This approach was achieved through the combination of 4-substituted phthalazin-1(2H)-ones 9a, b or 14a, b with sulfanilamide 1a, sulfathiazole 1b or sulfadiazine 1c through amide linkers 6a

  RAB1 5是一种领先的抗菌剂，其中甲氧苄啶与酞嗪部分连接。同样，我们在这项研究中的策略取决于某些磺胺类药物和某些酞菁-1（2 H）-one支架之间的相互连接，以增强其抗菌活性。通过将4-取代的酞菁-1（2 H）-酮9a，b或14a，b与磺酰胺1a，磺胺噻唑1b或磺胺嘧啶1c通过酰胺连接基6a，b结合使用以产生目标化合物10a，从而实现了该方法。– d和15a – e。新合成的化合物的抗菌活性表明，所有测试的化合物均具有比其参考磺胺药物1a - c更高的抗菌活性。化合物10c对革兰氏阳性细菌肺炎链球菌和金黄色葡萄球菌具有最高的抗菌活性，MIC = 0.39μmol/ mL。此外，化合物10d对革兰氏阴性菌大肠杆菌和鼠伤寒沙门氏菌分别具有MIC = 0.39和0.78μmol/ mL的优异抗菌活性。
• Aurora kinase modulators and method of use
  申请人：Cee J. Victor

  公开号：US20070185111A1

  公开（公告）日：2007-08-09

  The present invention relates to chemical compounds having a general formula I wherein A 1 , A 2 , C 1 , C 2 , D, L 1 , L 2 , Z and R 1 - are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1、A2、C1、C2、D、L1、L2、Z和R1-在此定义，并且具有调节各种蛋白激酶受体酶的能力，从而影响与这些激酶活动相关的各种疾病状态和病况。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，用于治疗癌症和癌症相关疾病。该发明还包括含有这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• The imidazo[2,1-a]isoindole system. A new skeletal basis for antiplasmodial compounds
  作者：Esther del Olmo、Marlon Garcı́a Armas、Mª Inés Ybarra、Josè Luis López、Patricia Oporto、Alberto Giménez、Eric Deharo、Arturo San Feliciano

  DOI：10.1016/s0960-894x(03)00509-2

  日期：2003.8

  imidazo[2,1-a]isoindole and pyrimido[2,1-a]isoindole derivatives related to the natural dihydrostilbenoid isonotholaenic acid is reported. The evaluation was performed on cultures of F32 strain of Plasmodium falciparum and potent representative compounds were also evaluated in the ferriprotoporphyrin IX biomineralization inhibition test (FBIT). Compounds having the imidazo[2,1-a]isoindole skeleton

  报道了一些与天然二氢苯乙烯基异戊二烯酸相关的二氢苯乙烯基酰胺，邻苯二酮，咪唑并[2,1-a]异吲哚和嘧啶基[2,1-a]异吲哚衍生物的体外抗血浆活性。对恶性疟原虫的F32菌株的培养物进行了评估，并且还在铁原卟啉IX生物矿化抑制试验（FBIT）中评估了有效的代表性化合物。具有咪唑并[2，1-a]异吲哚骨架的化合物活性最高，该组中的一种化合物与氯喹一样有效，但通过抑制血红素生物矿化的机制起作用。
• Leishmanicidal activity of some stilbenoids and related heterocyclic compounds
  作者：Esther del Olmo、Marlon Garcı́a Armas、Jose Luis López-Pérez、Victoria Muñoz、Eric Deharo、Arturo San Feliciano

  DOI：10.1016/s0960-894x(01)00387-0

  日期：2001.8

  the leishmanicidal activity of some natural and semisynthetic dihydrostilbenoids and several compounds of other series of dihydrostilbamides, isoindoles, phthalazinones, imidazoisoindoles and pyrimidoisoindoles. The evaluation was performed in vitro, on cultures of cutaneous, mucocutaneous and visceral strains of Leishmania spp. The most potent and selective compounds of these series were the dihydrostilbene

  我们已经评估了一些天然和半合成的二氢二苯乙烯类化合物和其他系列的二氢二苯乙烯酰胺，异吲哚，邻苯二氮酮，咪唑异吲哚和嘧啶异吲哚的几种化合物的杀菌活性。评估是在体外对利什曼原虫属的皮肤，粘膜皮肤和内脏菌株的培养物进行的。这些系列中最有效和选择性最大的化合物是二氢sti哌啶。